Medtronic Announces Major Leadership Appointment: Former Johnson & Johnson Executive Eric Lenard Named VP and CFO of Innovation, R&D, and Quality

Source: Medical Device Business Review

Recently, according to overseas sources,MedtronicAnnouncement of AppointmentFormer Johnson & Johnson ExecutiveEric LenardServing in a newly established position—Vice President, Innovation, R&D and Quality & Chief Financial Officer。

Medtronic Chief Financial OfficerThierry Pieton has posted on LinkedIn, announcing Eric Lenard's appointment.

It is understood that Lenard possesses extensive financial expertise in the medical device industry, with a rich track record of long-term service to innovative healthcare companies. Prior to joining Medtronic, he held multiple senior management positions at another healthcare giant, Johnson & Johnson.

Lenard has dedicated 22 years to Johnson & Johnson., having held multiple core management positions throughout his/her career, with the final role beingVice President, Global Services Finance, for a term of nearly four years; during which he/she also served asVice President and Chief Financial Officer, Johnson & Johnson Robotics and Digital Business, and was responsible for the financial operations management of business units such as DePuy Synthes and Ethicon. Prior to joining Johnson & Johnson,Lenard served at Procter & Gamble for over six years., holding multiple finance-related positions.

Medtronic’s New Vice President and Chief Financial Officer of Innovation, Development, and QualityEricLenard

The positions established this time directlyIntegrate the three core pillars of innovation, R&D, and qualityFinancial Work, distinct from the traditional model in which the Group CFO oversees the finances of the entire company, to achieve vertical specialized management.Pieton stated, “This is a newly established position at Medtronic and a key step in our ongoing process of increasing investment in innovation.”

“This role will deeply integrate the finance function into the company’s end-to-end R&D process, overseeing the prioritization of R&D projects, capital allocation, and execution, thereby helping the company’s innovation pipeline create greater clinical value and deliver more benefits to patients, while achieving long-term value growth.”PietonHe concluded by stating, “I look forward to collaborating with him to further strengthen the financial control framework for the company’s innovative business segments, thereby enhancing process rigor, execution compliance, and information transparency.”

Public information indicates that in fiscal year 2026, Medtronic continued to advance small-scale strategic acquisitions while simultaneously increasing investment in the internal development of cutting-edge technologies. Its R&D expenditure growth has long outpaced revenue growth, continuously exerting downward pressure on gross margin performance.

Upon assuming office, Eric Lenard will, throughThree-Layer ActionImprove Capital Efficiency: Divest early-stage pipeline assets with limited commercial potential, extend budget allocations for the development cycles of high-potential disruptive products, and centrally manage global multi-center clinical trial costs to gradually restore gross margins and achieve the company’s high single-digit EPS growth target. Meanwhile, implement unified financial management for the quality sector to proactively forecast compliance costs arising from regulatory updates worldwide, mitigate additional expenditures caused by policy changes in MDR and FDA regulations, and ensure a stable pace for overseas registration of innovative products.

In summary,Medtronic’s establishment of a dedicated CFO role for innovation, R&D, and quality is not merely an isolated executive personnel change, but a landmark signal of the shifting growth logic in the global medical device industry.In the past, industry giants relied on high-margin consumables to cover extensive R&D investments. Today, under the triple pressures of centralized procurement, stringent global regulations, and pipeline diversification, the era of merely pursuing the scale of R&D investment has come to an end, with return on investment efficiency becoming the core performance metric.